WO2001017527A1 - Agents destines a la prevention et a au traitement des maladies des yeux - Google Patents
Agents destines a la prevention et a au traitement des maladies des yeux Download PDFInfo
- Publication number
- WO2001017527A1 WO2001017527A1 PCT/JP2000/006014 JP0006014W WO0117527A1 WO 2001017527 A1 WO2001017527 A1 WO 2001017527A1 JP 0006014 W JP0006014 W JP 0006014W WO 0117527 A1 WO0117527 A1 WO 0117527A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- eye
- preventive
- agent
- therapeutic agent
- aqueous suspension
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/222—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having aromatic groups, e.g. dipivefrine, ibopamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
Definitions
- the present invention relates to a prophylactic and / or therapeutic agent for eye diseases having an inhibitory activity on elastase activity derived from leukocytes (neutrophils).
- Japanese Patent Publication No. 5 818 586 and Japanese Patent Application Laid-Open No. 5-19464 have an inhibitory effect on elastase activity derived from human neutrophils. And useful for the prevention and treatment of emphysema, atherosclerosis, rheumatoid arthritis, etc., Formula (I):
- Uveitis especially, beetle 6
- corneal conjunctivitis Various corneal conjunctivitis, spring catarrh, conjunctival allergy, uveitis, Behcet's disease, cataract postoperative inflammation and various ocular inflammatory diseases such as pseudopterygium, especially corneal conjunctival inflammatory diseases (for example, corneal herpes, bacterial cornea) Inflammation, bacterial conjunctivitis, fungal keratitis, acanthamoeba keratitis, corneal trauma, alkaline keratoconjunctivitis, corneal ulcer, corneal malacia due to vitamin A deficiency, necrotizing keratitis, neuropathic keratitis, diabetic It is useful for the prevention and treatment of keratopathy, keratoconjunctivitis sicca, keratoconjunctivitis with contact lenses, spring catarrh, conjunctival allergy, etc.).
- the prophylactic or therapeutic agent for ophthalmic diseases of the present invention is mixed with a pharmacologically acceptable carrier, excipient, diluent, or the like known per se, and in accordance with a method known per se, for example, tablets, capsules, Various oral and parenteral pharmaceutical or veterinary compositions such as granules, injections, eye drops, and ophthalmic ointments can be prepared. Particularly, dosage forms for topical administration, preferably eye drops It is desirable to use it as an ointment.
- eye drops examples include non-aqueous eye drops such as aqueous eye drops, aqueous suspension eye drops, viscous eye drops, and solubilized eye drops, non-aqueous eye drops, and non-aqueous 14 suspension eye drops.
- non-aqueous eye drops such as aqueous eye drops, aqueous suspension eye drops, viscous eye drops, and solubilized eye drops, non-aqueous eye drops, and non-aqueous 14 suspension eye drops.
- aqueous eye drops are preferred.
- aqueous suspension ophthalmic solutions are especially preferred.
- Aqueous eye drops include various commonly used additives such as buffers (eg, phosphate buffer, borate buffer, citrate buffer, tartrate buffer, acetate buffer, amino acid) , Sodium acetate, sodium citrate, etc.), tonicity agents (eg, saccharides such as sorbitol, glucose, mannitol, polyhydric alcohols such as glycerin, concentrated glycerin, polyethylene dalicol, propylene dalicol, sodium chloride) Salts, etc.), preservatives or preservatives (eg, benzalkonium chloride, benzethonium chloride, para-hydroxybenzoates such as methyl para-hydroxybenzoate and ethyl para-hydroxybenzoate, benzyl alcohol, phenethyl alcohol, sorbic acid) Or its salt, thimerosal, chlorobutanol ), Dissolution aids or stabilizers (eg, cyclodextrins and derivatives thereof, water-
- Conditioning agents eg, hydrochloric acid, acetic acid, phosphoric acid, sodium hydroxide, water 7 Potassium oxide, ammonium hydroxide, etc.
- thickeners eg, hydroxyxethyl cellulose, hydroxypropyl senorellose, methinolecellulose, hydroxypropylmethylcellulose, carboxymethylcellulose and its salts
- chelate Agents eg, sodium edetate, sodium citrate, condensed sodium phosphate, etc.
- Aqueous suspension ophthalmic solutions include the above additives, as well as suspending agents (eg, polyvinylpyrrolidone, glyceryl monostearate, etc.) and dispersants (eg, surfactants such as tyloxapol, polysorbate 80, etc.)
- suspending agents eg, polyvinylpyrrolidone, glyceryl monostearate, etc.
- dispersants eg, surfactants such as tyloxapol, polysorbate 80, etc.
- An aqueous suspension ophthalmic solution having more uniform fine particles and good dispersibility can be produced by blending an agent, an ionic polymer such as sodium alginate).
- aqueous suspension ophthalmic solution When producing the aqueous suspension ophthalmic solution, it is preferable to use a pH adjusting agent to make the acidic side (pH 4 to 5.5). Hydrochloric acid is preferred as the pH adjuster.
- a buffering agent to be added to the aqueous suspension ophthalmic solution sodium citrate or sodium acetate is preferable. Don is preferred.
- a surfactant and Z or sodium alginate are preferred.
- the surfactant is preferably tyloxabol or polysorbate 80.
- ophthalmic ointment As the ophthalmic ointment, known ointment bases such as purified lanolin, vaseline, plastibase, liquid paraffin, polyethylene glycol and the like are used.
- the prophylactic and / or therapeutic agent of the present invention can be administered to mammals (eg, humans, puppies, dogs, cats, puppies, puppies, monkeys, etc.) suffering from or at risk of eye diseases. it can.
- the administration route and dosage vary depending on the condition, age, weight, etc. of the patient. 1
- a free compound of the formula (I) about 0.000 :! / v)%, preferably about 0.01 to 3 (w / v)%, as an aqueous ophthalmic solution containing 1 to several drops per dose 1 to 8 times daily depending on symptoms It is desirable.
- the prophylactic and therapeutic agents of the present invention further include other pharmacologic agents, for example, steroid anti-inflammatory agents (dexamethasone, prednisolone, etc.), non-steroidal anti-inflammatory agents (diclofenac sodium, Pranoprofen), antiallergic agents (tranilast, ketotifen fumarate, sodium cromoglycate, etc.), antihistamines (diphenhydramine hydrochloride, etc.), glaucoma drugs (pilocarpine hydrochloride, physostigmine salicylate, thymolitol, isopropyl unoprostone, etc.) ), Antibiotics (gentamicin sulfate, fradiomycin sulfate, tobramycin, snorevenicillin, cefmenoxime, erythromycin, colistin, oxytetracycline, polymyxin B, chloramphenicone) , Micronomycin, dibekacin, sis
- the prophylactic and / or therapeutic agent of the present invention is particularly useful in the prevention and / or treatment of inflammation due to ocular infections, ulcer ulcers, etc., together with at least one of the above antibiotics, antibacterial agents, antiviral agents and antifungal agents. Preferably, it is used.
- antibiotics, antibacterials, antivirals and antifungals may be combined with the prophylactic and therapeutic agents of the present invention or may be individually instilled.
- the prophylactic and therapeutic agents of the present invention and the antibiotics, antibacterial agents, antiviral agents and antifungal agents may be instilled simultaneously, or may be instilled at regular intervals.
- the mixture was divided into four groups, and a mixture of equal amounts of 5% ketamine hydrochloride and 2% xylazine hydrochloride was intramuscularly administered in an amount of 1 mL / kg, and general anesthesia was performed.
- Endotoxin 1 derived from Pseudomonas aeruginosa dissolved in physiological saline. /.
- Each 10 ⁇ L of the solution was injected into the stroma of the cornea of both eyes of a egret.
- the animals were divided into four groups, and the rabbits were subjected to general anesthesia by intramuscular administration of a mixture of equal amounts of 5% ketamine hydrochloride and 2% xylazine hydrochloride, and topical ophthalmic anesthesia with oxybuproforcein.
- a filter paper having a diameter of 1 Omm soaked in 2N Na ⁇ H was brought into contact with the center of the cornea of the right eye of the egret for 1 minute to create alkaline corrosion, and immediately washed with a physiological saline solution of 1 OmL or more.
- Alkaline corrosion The depth of corneal ulcer and the observation of new blood vessels were observed using a slit lamp from the 5th day to every 30th day using a slit lamp. Ophthalmic administration of each test substance was started immediately after alkaline corrosion, and thereafter, 20 ⁇ L was instilled four times daily every 2 hours.
- No corneal ulcer is observed. 0 There is an ulcer at a depth of less than 1/3 from the corneal surface into the anterior chamber. 1 An ulcer is found at a depth of 1/3 or more and less than 2/3 from the corneal surface into the anterior chamber. ⁇ 2 Ulcers are observed at a depth of 2/3 or more from the corneal surface into the anterior chamber. 3 Perforations are observed in the cornea. Four
- FIGS. 1 to 3 ° after endotoxin injection The time course of corneal inflammation from day 5 to day 3 ° after endotoxin injection is shown in FIGS.
- the control group In the control group, all symptoms peaked on day 15 and then gradually recovered, and almost disappeared on day 30.
- Compound A ophthalmic solution In the group administered with Compound A ophthalmic solution, an inhibitory effect on the control group was observed in all items of corneal opacity, corneal ulcer and angiogenesis.
- Figure 4 shows the total score of each group on the 15th day when each symptom reaches the peak.
- the inhibition rate of the compound A ophthalmic solution administration group with respect to the control group was 59.4%, There was also a significant difference.
- betamethasone phosphate ophthalmic solution used as a positive control in this study showed a very strong anti-inflammatory effect.However, in clinical ocular infections, long-term administration of steroids also has the side effect of exacerbating infection. However, its use is often restricted.
- Compound A ophthalmic solution which is considered to have a low risk of exacerbation of infection, is an effective drug for ocular infections.
- FIG. 57 shows the time course of corneal inflammation from day 5 to day 30 after corneal alkali treatment.
- the peak reached 20 to 25 days after the corneal alkali treatment.
- 12 In the group administered with Compound A ophthalmic solution, a significant inhibitory effect was observed on corneal ulcer on the 20th day. No inhibitory effect was observed on vascularization and corneal opacity.
- 0.1% betamethasone phosphate instillation group which was used as a positive control, significant inhibition of vascular neogenesis was observed on the 15th day.
- Compound A When administering Compound A, Compound A was suspended in a base (0.1% sodium acetate, 0.1% polysorbate 80, 0.9% NaC1; pH 5.0) 1.0% Compound A ophthalmic solution was used. 0.3% lomefloxacin hydrochloride (LFLX) ophthalmic solution was used as an antibacterial agent, and physiological saline was used as a control substance.
- a base 0.1% sodium acetate, 0.1% polysorbate 80, 0.9% NaC1; pH 5.0
- Compound A ophthalmic solution 0.3% lomefloxacin hydrochloride (LFLX) ophthalmic solution was used as an antibacterial agent, and physiological saline was used as a control substance.
- LFLX lomefloxacin hydrochloride
- the pathogenic bacterium used was an ophthalmic clinical isolate Pseudomonas aeruginosa E-134. ⁇ After performing a general anesthesia with 5% ketamine hydrochloride and 2% xylazine hydrochloride (equivalent mixture), 3.9 x 10 4 C FU / mL in a 100 ⁇ L micro syringe with a 30 G needle The bacterial suspension 30 / XL (1.17 ⁇ 10 3 CF UZ cornea) was injected into the corneal stroma of one eye for inoculation.
- corneal ulcers were observed and scored according to the criteria for scoring corneal lesions in Table 2 (Barletta JP et al., Invest Ophthalmol Vis Sci 37: 20-28, 1996.) .
- the corneal ulcer is larger than 1/4 of the whole cornea and smaller than 1/2. Hence 2
- the corneal ulcer is larger than 1/2 of the whole cornea and smaller than 3/4.
- Corneal ulcers are larger than 3/4 of the entire cornea.
- Example 1 An aqueous ophthalmic solution was prepared according to the following formulation.
- Sterile Purified Water Total lOOmL (pH 6.0) Compound A, sodium chloride, sodium acetate and benzalkonium chloride were dissolved in about 8 OmL of purified water. The pH was adjusted to 6.0 with hydrochloric acid and sodium hydroxide. Sterile purified water was added to make the total amount 10 OmL, and an aqueous ophthalmic solution was prepared.
- An aqueous suspension ophthalmic solution was prepared according to the following formulation.
- Sterile purified water Total volume l O OmL (pH 5.0) Sodium chloride, sodium acetate, polysorbate 80 and benzalkonium chloride were dissolved in about 80 mL of purified water. The pH was adjusted to 5.0 with hydrochloric acid and sodium hydroxide, compound A was added, and the mixture was uniformly suspended with a homogenizer. Sterile purified water was added to make the total volume 1 O OmL to prepare an aqueous suspension ophthalmic solution.
- An aqueous suspension ophthalmic solution was prepared according to the following formulation.
- Sterile purified water A total amount of 10 OmL (pH 5.0) About 8 Oml of purified water was heated to dissolve methyl paraoxybenzoate and propyl paraoxybenzoate. Hydroxypropylmethylcellulose was dispersed in this solution, and then cooled to room temperature to dissolve. Concentrated glycerin and sodium acetate were added to this solution, and the pH was adjusted to 5.0 with hydrochloric acid and sodium hydroxide. To this solution was added Compound A, and the mixture was uniformly suspended with a homogenizer. Sterile purified water was added to make a total volume of 10 OmL to prepare an aqueous suspension ophthalmic solution. 16
- An eye ointment was prepared according to the following formulation.
- Aqueous suspension ophthalmic solution was prepared according to the following formulation
- Sodium citrate, concentrated glycerin, methyl parahydroxybenzoate, propyl parahydroxybenzoate, propylene glycol and polybutylpyrrolidone were dissolved in about 8 OmL of purified water. After dissolving Compound A in this solution and filtering through a 0.22 ⁇ membrane filter, ⁇ 5.0 was adjusted with hydrochloric acid to precipitate fine crystals (2 to 3 ⁇ ) of Compound ⁇ . Sodium alginate was dissolved and purified water was added to make a total volume of 10 OmL to prepare an aqueous suspension ophthalmic solution.
- Aqueous suspension ophthalmic solution was prepared according to the following formulation
- Sodium citrate, concentrated glycerin, methyl paraoxybenzoate, propyl paraoxybenzoate, propylene glycol and polyvier pyrrolidone were dissolved in about 8 OmL of purified water.
- Compound A was dissolved in this solution, filtered through a 0.22 ⁇ m membrane filter, and adjusted to pH 5.0 with hydrochloric acid to precipitate fine crystals of compound A (2 to 3 m).
- Sodium alginate and tyloxapol were dissolved, purified water was added to make a total volume of 10 OmL, and an aqueous suspension ophthalmic solution was prepared.
- An aqueous suspension ophthalmic solution was prepared according to the following formulation.
- An aqueous suspension ophthalmic solution was prepared according to the following formulation.
- the pharmaceutical or veterinary pharmaceutical composition useful for prevention and treatment of eye diseases, especially eye inflammatory diseases and corneal ulcers can be provided.
Description
Claims
Priority Applications (11)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
HU0202745A HUP0202745A2 (hu) | 1999-09-06 | 2000-09-05 | Profilaktikus és terápiás szerek szembetegségek kezelésére |
JP2001521318A JP4682495B2 (ja) | 1999-09-06 | 2000-09-05 | 眼疾患の予防、治療剤 |
NZ517556A NZ517556A (en) | 1999-09-06 | 2000-09-05 | N-[o-(p-pivaloyloxybenzenesulphonyl-amino)benzoyl]glycine as preventive and therapeutic agents for eye diseases |
MXPA02002452A MXPA02002452A (es) | 1999-09-06 | 2000-09-05 | Agentes preventivos y terapeuticos para enfermedades de oftalmicas. |
US10/070,307 US6624193B1 (en) | 1999-09-06 | 2000-09-05 | Preventive and therapeutic agents for eye diseases |
KR1020027002991A KR20020042667A (ko) | 1999-09-06 | 2000-09-05 | 안질환 예방 및 치료제 |
AU68708/00A AU6870800A (en) | 1999-09-06 | 2000-09-05 | Preventive and therapeutic agents for eye diseases |
CA002383971A CA2383971A1 (en) | 1999-09-06 | 2000-09-05 | Prophylactic and therapeutic medicaments for ophthalmic diseases |
BR0013793-6A BR0013793A (pt) | 1999-09-06 | 2000-09-05 | Medicamentos profiláticos e terapêuticos para doenças oftálmicas |
EP00956927A EP1213018A4 (en) | 1999-09-06 | 2000-09-05 | AGENTS FOR THE PREVENTION AND TREATMENT OF EYE DISEASES |
NO20021094A NO20021094L (no) | 1999-09-06 | 2002-03-05 | Profylaktiske og terapeutiske medikamenter for oftalmologiske sykdommer |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP25153899 | 1999-09-06 | ||
JP11/251538 | 1999-09-06 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2001017527A1 true WO2001017527A1 (fr) | 2001-03-15 |
WO2001017527A9 WO2001017527A9 (en) | 2001-06-21 |
Family
ID=17224318
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2000/006014 WO2001017527A1 (fr) | 1999-09-06 | 2000-09-05 | Agents destines a la prevention et a au traitement des maladies des yeux |
Country Status (14)
Country | Link |
---|---|
US (1) | US6624193B1 (ja) |
EP (1) | EP1213018A4 (ja) |
JP (1) | JP4682495B2 (ja) |
KR (1) | KR20020042667A (ja) |
CN (1) | CN1387436A (ja) |
AU (1) | AU6870800A (ja) |
BR (1) | BR0013793A (ja) |
CA (1) | CA2383971A1 (ja) |
HU (1) | HUP0202745A2 (ja) |
MX (1) | MXPA02002452A (ja) |
NO (1) | NO20021094L (ja) |
NZ (1) | NZ517556A (ja) |
WO (1) | WO2001017527A1 (ja) |
ZA (1) | ZA200201819B (ja) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004064817A1 (ja) * | 2003-01-22 | 2004-08-05 | Nichiban Co., Ltd. | 眼疾患治療用経皮吸収型製剤、その使用、及び眼疾患治療薬の眼の局所組織への移行方法 |
JP5000835B2 (ja) * | 2000-08-25 | 2012-08-15 | 千寿製薬株式会社 | 水性懸濁液剤 |
JP2016517427A (ja) * | 2013-03-14 | 2016-06-16 | パンオプティカ,インコーポレイテッド | 後眼部へ薬物を送達するための眼用製剤 |
Families Citing this family (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6552082B2 (en) * | 2000-06-29 | 2003-04-22 | Ono Pharmaceutical Co., Ltd. | Solution of N-[o-(p-pivaloyloxybenzenesulfonylamino)benzoyl] glycine monosodium salt tetra-hydrate and drug product thereof |
US7315848B2 (en) * | 2001-12-12 | 2008-01-01 | Aaron Pearse | Web snippets capture, storage and retrieval system and method |
EP1586316B1 (en) | 2003-01-21 | 2008-04-30 | Senju Pharmaceutical Co., Ltd. | Aqueous liquid preparation containing 2-amino-3-(4-bromobenzoyl)phenylacetic acid |
US8748402B2 (en) | 2004-06-07 | 2014-06-10 | Bausch & Lomb Pharma Holdings Corp. | Ophthalmic formulations and uses thereof |
US8372814B2 (en) * | 2004-06-07 | 2013-02-12 | Ista Pharmaceuticals, Inc. | Ophthalmic formulations and uses thereof |
US20070208058A1 (en) * | 2004-10-25 | 2007-09-06 | Bryant Roy W | Stable Pharmaceutical Compositions and Methods of Making and Using Same |
US20100160293A1 (en) * | 2005-02-17 | 2010-06-24 | Kakuji Tojo | Solid Ophthalmic Drug for External Use |
HUE063927T2 (hu) | 2006-09-29 | 2024-02-28 | Johnson & Johnson Vision Care | Szemallergiák kezelésében alkalmazott eljárások és szemészeti eszközök |
MX2009011801A (es) * | 2007-05-04 | 2009-11-13 | Baush & Lomb Inc | Composiciones para reducir, aminorar, tratar o evitar afeccion de ojo seco y metodos para elaboracion y uso de las mismas. |
WO2008137826A2 (en) * | 2007-05-07 | 2008-11-13 | Bausch & Lomb Incorporated | Compositions for reducing, ameliorating, treating, or preventing condition of dry eye and methods of making and using same |
US8300252B2 (en) * | 2008-06-18 | 2012-10-30 | Livescribe, Inc. | Managing objects with varying and repeated printed positioning information |
TW201023912A (en) * | 2008-12-05 | 2010-07-01 | Alcon Res Ltd | Pharmaceutical suspension |
US8912236B2 (en) * | 2009-03-03 | 2014-12-16 | Alcon Research, Ltd. | Pharmaceutical composition for delivery of receptor tyrosine kinase inhibiting (RTKi) compounds to the eye |
BRPI1008920A2 (pt) * | 2009-03-03 | 2015-08-25 | Alcon Res Ltd | Composição farmacêutica para liberação de compostos inibidores de receptor de tirosina quinase (rtki) para o olho |
US10383885B2 (en) | 2015-06-16 | 2019-08-20 | Rong-Tsun Wu | Method for treating or preventing dry eyes |
US11058713B2 (en) * | 2017-06-29 | 2021-07-13 | Advaite LLC. | Treatment and diagnosis of ocular surface disorders |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0347168A1 (en) * | 1988-06-13 | 1989-12-20 | Ono Pharmaceutical Co., Ltd. | Derivatives of p-substituted phenyl ester of pivalic acid |
WO1990004409A1 (en) * | 1988-10-27 | 1990-05-03 | University Of Kentucky Research Foundation | Human leukocyte elastase inhibitors and methods of producing and using same |
EP0539223A1 (en) * | 1991-10-25 | 1993-04-28 | Ono Pharmaceutical Co., Ltd. | Glycine derivative monosodium salt tetrahydrate having an inhibitory effect on elastase |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0320253A (ja) * | 1988-06-13 | 1991-01-29 | Ono Pharmaceut Co Ltd | ピバル酸 p―置換フェニルエステル誘導体、それらの製造方法およびそれらを有効成分として含有するエラスターゼ阻害剤 |
ATE161016T1 (de) | 1991-06-18 | 1997-12-15 | Fujisawa Pharmaceutical Co | Ws7622a enthaltende prophylaktische/therapeutische zusammensetzung zur vorbeugung und behandlung von verstreuter, intravaskulärer koagulation, chronischer, infektiöser atemwegskrankheiten oder chronischer bronchitis |
GB9115811D0 (en) | 1991-07-22 | 1991-09-04 | Fujisawa Pharmaceutical Co | Fr901451 substance,process for preparation thereof and use thereof |
JPH05194366A (ja) * | 1991-10-25 | 1993-08-03 | Ono Pharmaceut Co Ltd | グリシン誘導体・モノナトリウム塩・4水和物、その製造方法、それを含有する薬剤および該誘導体の中間体の製造方法 |
-
2000
- 2000-09-05 MX MXPA02002452A patent/MXPA02002452A/es unknown
- 2000-09-05 CA CA002383971A patent/CA2383971A1/en not_active Abandoned
- 2000-09-05 JP JP2001521318A patent/JP4682495B2/ja not_active Expired - Fee Related
- 2000-09-05 EP EP00956927A patent/EP1213018A4/en not_active Withdrawn
- 2000-09-05 CN CN00815442A patent/CN1387436A/zh active Pending
- 2000-09-05 AU AU68708/00A patent/AU6870800A/en not_active Abandoned
- 2000-09-05 HU HU0202745A patent/HUP0202745A2/hu unknown
- 2000-09-05 KR KR1020027002991A patent/KR20020042667A/ko not_active Application Discontinuation
- 2000-09-05 BR BR0013793-6A patent/BR0013793A/pt not_active IP Right Cessation
- 2000-09-05 NZ NZ517556A patent/NZ517556A/en unknown
- 2000-09-05 WO PCT/JP2000/006014 patent/WO2001017527A1/ja not_active Application Discontinuation
- 2000-09-05 US US10/070,307 patent/US6624193B1/en not_active Expired - Fee Related
-
2002
- 2002-03-05 NO NO20021094A patent/NO20021094L/no not_active Application Discontinuation
- 2002-03-05 ZA ZA200201819A patent/ZA200201819B/xx unknown
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0347168A1 (en) * | 1988-06-13 | 1989-12-20 | Ono Pharmaceutical Co., Ltd. | Derivatives of p-substituted phenyl ester of pivalic acid |
WO1990004409A1 (en) * | 1988-10-27 | 1990-05-03 | University Of Kentucky Research Foundation | Human leukocyte elastase inhibitors and methods of producing and using same |
EP0539223A1 (en) * | 1991-10-25 | 1993-04-28 | Ono Pharmaceutical Co., Ltd. | Glycine derivative monosodium salt tetrahydrate having an inhibitory effect on elastase |
Non-Patent Citations (3)
Title |
---|
A. SPIERER ET AL.: "The effect of 2-marceptoacetyl-L-phenylalanyl-L-leucine, a specific inhibitor of Pseudomonas aeruginosa elastase, on experimental Pseudomonas keratitis in rabbit eyes", CURR. EYE RES., vol. 3, no. 4, 1984, pages 645 - 650, XP002934287 * |
J. CEJKOVA ET AL.: "Histochemical changes in the rabbit cornea and plasmin activity in the tear fluid during contact lens wear. Favourable influence of protease inhibitors (aprotinin, PC5, elastatinal)", HISTOCHEMISTRY, vol. 97, no. 1, 1992, pages 69 - 76, XP002934286 * |
See also references of EP1213018A4 * |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP5000835B2 (ja) * | 2000-08-25 | 2012-08-15 | 千寿製薬株式会社 | 水性懸濁液剤 |
US8658703B2 (en) | 2000-08-25 | 2014-02-25 | Senju Pharmaceutical Co., Ltd. | Aqueous suspension preparations |
WO2004064817A1 (ja) * | 2003-01-22 | 2004-08-05 | Nichiban Co., Ltd. | 眼疾患治療用経皮吸収型製剤、その使用、及び眼疾患治療薬の眼の局所組織への移行方法 |
JP2016517427A (ja) * | 2013-03-14 | 2016-06-16 | パンオプティカ,インコーポレイテッド | 後眼部へ薬物を送達するための眼用製剤 |
US10092549B2 (en) | 2013-03-14 | 2018-10-09 | Panoptica, Inc. | Ocular formulations for drug-delivery to the posterior segment of the eye |
US10307404B1 (en) | 2013-03-14 | 2019-06-04 | Panoptica, Inc. | Ocular formulations for drug-delivery to the posterior segment of the eye |
Also Published As
Publication number | Publication date |
---|---|
CN1387436A (zh) | 2002-12-25 |
NO20021094D0 (no) | 2002-03-05 |
KR20020042667A (ko) | 2002-06-05 |
CA2383971A1 (en) | 2001-03-15 |
MXPA02002452A (es) | 2004-09-10 |
BR0013793A (pt) | 2002-05-14 |
JP4682495B2 (ja) | 2011-05-11 |
EP1213018A1 (en) | 2002-06-12 |
NZ517556A (en) | 2003-08-29 |
ZA200201819B (en) | 2003-05-28 |
AU6870800A (en) | 2001-04-10 |
NO20021094L (no) | 2002-05-06 |
EP1213018A4 (en) | 2004-04-14 |
HUP0202745A2 (hu) | 2003-01-28 |
US6624193B1 (en) | 2003-09-23 |
WO2001017527A9 (en) | 2001-06-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2001017527A1 (fr) | Agents destines a la prevention et a au traitement des maladies des yeux | |
JP3683595B2 (ja) | セチリジン含有抗アレルギー点眼点鼻用組成物 | |
KR100889170B1 (ko) | 안구 건조의 치료에 있어서 리멕솔론의 용도 | |
RU2406499C2 (ru) | Профилактическое или терапевтическое средство для лечения кератоконъюнктивитных нарушений | |
JP6060168B2 (ja) | レバミピドと涙液保持作用を有する薬剤からなる前眼部疾患治療剤 | |
WO1993024121A1 (en) | Remedy for glaucoma | |
WO2013078998A1 (en) | Novel slow-releasing ophthalmic compositions comprising povidone iodine | |
US6403598B1 (en) | Ophthalmic composition | |
JP3527256B2 (ja) | 抗アレルギー点眼剤 | |
JPH0930966A (ja) | 眼科用新規製剤 | |
JP3502574B2 (ja) | 眼感染症治療用眼軟膏剤 | |
KR100193406B1 (ko) | 근시의 예방 및 치료용 조성물 | |
EP1876175B1 (en) | Therapeutic agent for corneal disease | |
WO2012068998A2 (zh) | 一种曲安奈德眼用制剂及其制备方法 | |
WO2002040028A1 (fr) | Gouttes pour les yeux en gel antibacterien | |
TW304879B (ja) | ||
EP1380302B1 (en) | Remedies for retina and choroid diseases containing steroids as the active ingredient | |
KR20150090045A (ko) | 피나플록사신 현탁 조성물 | |
CN110200904B (zh) | 一种降眼压缓释滴眼组合物及其制备方法 | |
JP3627801B2 (ja) | 副鼻腔炎の予防および/または治療剤 | |
JP2009528390A (ja) | 薬用ラトランキュリン製剤 | |
WO2007148744A1 (ja) | フマル酸誘導体を有効成分として含む角結膜障害の予防または治療剤 | |
JP2000007569A (ja) | 嗅覚障害治療剤 | |
JP3504656B2 (ja) | 水性医薬組成物 | |
WO2005032534A1 (ja) | 涙液異常の治療のための眼科用組成物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
AK | Designated states |
Kind code of ref document: C2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: C2 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
COP | Corrected version of pamphlet |
Free format text: PAGES 2-5, DESCRIPTION, ADDED |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 517556 Country of ref document: NZ |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2002/00569 Country of ref document: TR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2383971 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: PA/a/2002/002452 Country of ref document: MX Ref document number: 68708/00 Country of ref document: AU Ref document number: 1020027002991 Country of ref document: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2000956927 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 10070307 Country of ref document: US |
|
ENP | Entry into the national phase |
Ref document number: 2002 2002108719 Country of ref document: RU Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 008154422 Country of ref document: CN |
|
WWP | Wipo information: published in national office |
Ref document number: 1020027002991 Country of ref document: KR |
|
WWP | Wipo information: published in national office |
Ref document number: 2000956927 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWP | Wipo information: published in national office |
Ref document number: 517556 Country of ref document: NZ |
|
WWG | Wipo information: grant in national office |
Ref document number: 517556 Country of ref document: NZ |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 2000956927 Country of ref document: EP |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1020027002991 Country of ref document: KR |